The treatment of Wilms' tumour: results of the United Kingdom Children's Cancer Study Group (UKCCSG) second Wilms' tumour study

被引:81
作者
Mitchell, C [1 ]
Jones, PM
Kelsey, A
Vujanic, GM
Marsden, B
Shannon, R
Gornall, P
Owens, C
Taylor, R
Imeson, J
Middleton, H
Pritchard, J
机构
[1] Oxford Radcliffe Hosp, Oxford OX 9DU, England
[2] Royal Manchester Childrens Hosp, Manchester M27 1HA, Lancs, England
[3] Univ Wales Coll Med, Dept Histopathol, Cardiff CF4 4XN, S Glam, Wales
[4] Leicester Royal Infirm, Leicester LE1 5WW, Leics, England
[5] Birmingham Childrens Hosp, Dept Surg, Birmingham B4 6NH, W Midlands, England
[6] Great Ormond St Hosp Children, Dept Radiol, London WC1N 3JH, England
[7] Cookridge Hosp, Leeds LS16 6QB, W Yorkshire, England
[8] Univ Leicester, Data Ctr, UKCCSG, Leicester LE1 6TP, Leics, England
[9] Inst Child Hlth, London WC1N 3JH, England
关键词
Wilms' tumour; treatment; chemotherapy; radiotherapy; childhood cancer;
D O I
10.1054/bjoc.2000.1338
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aims of the UKW2 study were: (1) to further refine treatment for stage I and II favourable histology (FH) patients; (2) to consolidate the UKW1 results for stage III FH patients; (3) to improve the outlook for patients with inoperable primary tumours and those patients with stage IV and unfavourable histology disease. Treatment consisted of primary nephrectomy, wherever possible, followed by chemotherapy and radiotherapy, as dictated by stage and histology. Treatment was refined successfully for stage I and II FH patients. The 4-year event-free survival for these two groups was 94% and 91%, respectively. Stage III FH patients had a 4-year event free survival of 84%, The outlook for patients with clear cell sarcoma of the kidney is as good as for patients with favourable histology, whilst that for patients with anaplastic or rhabdoid variants remains poor. The outlook for the majority of children with Wilms' tumour is now excellent. (C) 2000 Cancer Research Campaign.
引用
收藏
页码:602 / 608
页数:7
相关论文
共 29 条
[1]   STATISTICAL-METHODS FOR ASSESSING OBSERVER VARIABILITY IN CLINICAL MEASURES [J].
BRENNAN, P ;
SILMAN, A .
BMJ-BRITISH MEDICAL JOURNAL, 1992, 304 (6840) :1491-1494
[2]  
DANGIO GJ, 1976, CANCER-AM CANCER SOC, V38, P633, DOI 10.1002/1097-0142(197608)38:2<633::AID-CNCR2820380203>3.0.CO
[3]  
2-S
[4]  
DANGIO GJ, 1981, CANCER-AM CANCER SOC, V47, P2302, DOI 10.1002/1097-0142(19810501)47:9<2302::AID-CNCR2820470933>3.0.CO
[5]  
2-K
[6]  
DANGIO GJ, 1989, CANCER-AM CANCER SOC, V64, P349, DOI 10.1002/1097-0142(19890715)64:2<349::AID-CNCR2820640202>3.0.CO
[7]  
2-Q
[8]   WILMS-TUMOR WITH PULMONARY METASTASES AT DIAGNOSIS - THE SIGNIFICANCE OF PRIMARY CHEMOTHERAPY [J].
DEKRAKER, J ;
LEMERLE, J ;
VOUTE, PA ;
ZUCKER, JM ;
TOURNADE, MF ;
CARLI, M .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) :1187-1190
[9]  
Godzinski J, 1999, Semin Urol Oncol, V17, P28
[10]   Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: A report from the National Wilms' Tumor Study group [J].
Green, DM ;
Breslow, NE ;
Beckwith, JB ;
Finklestein, JZ ;
Grundy, P ;
Thomas, PR ;
Kim, T ;
Shochat, S ;
Haase, G ;
Ritchey, M ;
Kelalis, P ;
D'Angio, GJ .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (12) :3744-3751